Melanoma - Causes and Molecular Basis

Melanoma: Etiology and Pathogenesis Introduction Melanoma is one of the most serious forms of skin cancer, and understanding how it develops requires examining both the external factors that trigger it and the internal mechanisms that allow tumor growth. This section explores the various causes of melanoma (its etiology) and how the disease develops and progresses in the body (its pathogenesis). This knowledge is foundational for understanding risk stratification, prevention, and treatment decisions. Etiology: What Causes Melanoma? Ultraviolet Radiation Exposure Ultraviolet (UV) radiation is the primary cause of melanoma. This radiation comes mainly from sunlight, though indoor tanning devices are also significant sources. UV radiation damages melanocytes (the pigment-producing cells in the skin) by creating specific mutations in their DNA. UV radiation has two main components, each damaging DNA in different ways: Ultraviolet B (UVB) light (wavelengths 280–315 nm) directly creates damage in DNA called cyclobutane pyrimidine dimers. These are essentially cross-links between adjacent DNA bases that distort the DNA structure and prevent normal replication and function. Ultraviolet A (UVA) light (wavelengths 315–400 nm) damages DNA less directly but still harmfully. UVA light generates reactive oxygen species—unstable molecules that damage DNA and other cellular components as a secondary effect. This makes UVA damage more diffuse and harder to repair. An important clinical finding is that frequent, severe sunburns in childhood substantially increase melanoma risk. This suggests that melanoma risk isn't just about total lifetime sun exposure, but particularly about acute, intense exposures that cause visible burning. Tanning Beds The use of tanning beds before age 30 increases melanoma risk by approximately 75 percent. This is a critical preventive health message, especially for younger individuals who may use tanning beds for cosmetic reasons. The UV exposure from these devices concentrates significant radiation exposure in a short period. Genetic Risk Factors and Hereditary Patterns Approximately 5–12 percent of all melanomas have a hereditary component. This means that some families carry genes that substantially increase melanoma susceptibility. If you have a first-degree relative (parent, sibling, or child) with melanoma, your risk increases by about 1.74 times compared to someone without this family history. Even more striking: people with a personal history of melanoma have an 8.4-fold increased risk of developing a second melanoma. This suggests that the genetic or constitutional factors that allowed the first tumor to develop persist in the patient's remaining skin. Specific Gene Mutations and Molecular Risk Factors Different melanomas harbor different mutations, which has important implications for treatment selection. Understanding these mutations helps oncologists choose which targeted therapies may be effective. BRAF mutations occur in approximately 50 percent of cutaneous melanomas. The most common variant is BRAF V600E (and less commonly V600K). This mutation is clinically important because tumors with BRAF mutations respond well to BRAF inhibitors, a class of targeted drugs. BRAF normally acts as a "brake" in cell growth signaling, and when mutated, this brake is released, allowing uncontrolled proliferation. NRAS mutations occur in roughly 30 percent of melanomas. NRAS is another protein in cell growth pathways, and its mutation also promotes unchecked cell division. Tumor-suppressor genes can lose function in melanoma through mutations. Key examples include: NF1 (neurofibromin 1), which normally inhibits growth signaling TP53, the famous "guardian of the genome" that normally triggers cell death when DNA damage is too severe CDKN2A (encoding p16), which normally blocks cell cycle progression Loss of function in these genes removes the brakes on cell growth. MC1R gene variants are particularly interesting because they have a direct phenotypic link to melanoma risk. The MC1R gene encodes a receptor that controls skin pigmentation and sun protection mechanisms. Variants in MC1R—especially those associated with red hair and fair skin—increase melanoma risk by 2–3.6 times. People with these variants have less natural UV-protective pigmentation. Xeroderma pigmentosum is a rare inherited disorder affecting DNA repair enzymes. People with this condition have markedly elevated melanoma risk because they cannot properly repair UV-induced DNA damage, allowing mutations to accumulate. Phenotypic Risk Factors Beyond specific genes, certain visible characteristics correlate with melanoma risk. These phenotypic factors reflect both genetic predisposition and behavioral patterns. Moles and dysplastic nevi are important risk markers. Individuals with more than 50 moles have higher melanoma risk. More concerning is dysplastic nevus syndrome (atypical mole syndrome), a condition characterized by numerous atypical-appearing moles that have a substantially higher risk of transforming into melanoma. Skin, hair, and eye color matter significantly. Fair skin, red hair, and light eye color provide less natural protection from UV radiation. This is because these traits correlate with lower levels of the protective pigment melanin and often indicate MC1R gene variants as discussed above. Immunosuppression substantially increases melanoma risk. Organ transplant recipients who require long-term immunosuppressive medications have higher melanoma incidence, as do people with HIV infection. This suggests that the immune system normally plays a role in preventing melanoma development, likely through immune surveillance that detects and destroys precancerous cells. Pathogenesis: How Melanoma Develops and Grows Understanding how melanoma develops requires knowing that the disease progresses through distinct phases and that different depths of invasion carry different risks of spread. Growth Phases: Radial and Vertical Growth Melanoma progresses through two distinct growth patterns, each with different clinical implications: The radial growth phase is characterized by horizontal spread of tumor cells within the basal layer of the epidermis. During this phase, tumor cells spread outward along the epidermis but do not penetrate deeply. The thickness is usually less than 1 mm, and importantly, lesions in the radial growth phase rarely metastasize (spread to distant organs). These lesions can often be cured by surgical excision alone. The vertical growth phase represents a more dangerous transition. During this phase, tumor cells change behavior—they now invade vertically, pushing upward through the epidermis and downward into deeper skin layers (the papillary dermis and beyond). When thickness exceeds 1 mm, the risk of metastasis increases significantly. This vertical invasion suggests the cancer has acquired additional mutations that allow invasion and that enable it to enter blood vessels and lymph vessels for systemic spread. The transition from radial to vertical growth is a critical moment in melanoma evolution. Understanding this explains why early detection is so important—catching melanoma while still in the radial growth phase, before it invades deeply, provides the best prognosis. Depth Measurement and Staging Two complementary systems describe how deeply a melanoma has invaded: Breslow depth is a measurement in millimeters of the vertical thickness of the tumor from the top of the epidermis to the deepest tumor cell. This is the most practically useful measurement for staging and prognosis. A depth greater than 1 mm generally corresponds to the transition into vertical growth phase and carries higher metastatic risk. Clark level describes the anatomic layers involved: Level I: Confined to the epidermis Level II: Invading the papillary dermis Level III: Filling the papillary dermis Level IV: Invading the reticular (deeper) dermis Level V: Invading subcutaneous fat Levels IV and V indicate deep dermal or subcutaneous involvement and carry worse prognosis. <extrainfo> While Breslow depth is more commonly used in modern practice for prognostic assessment, Clark level provides useful anatomic context for understanding invasion patterns. Both are important to recognize when reading pathology reports. </extrainfo> Molecular Basis: UV-Induced DNA Damage The mechanism by which UV exposure causes melanoma involves specific, characteristic mutations. UV-induced cyclobutane pyrimidine dimers can cause cytosine-to-thymine (C>T) base transitions. This mutation pattern is so characteristic of UV damage that it's called the "UV fingerprint mutation." Finding this signature mutation pattern in a melanoma provides molecular evidence that UV exposure was the causative agent. This molecular understanding explains why prevention through sun protection is so important—every severe sunburn creates opportunities for these signature mutations to be fixed into melanocyte DNA. Immune Control and Regression Interestingly, the body has mechanisms to fight developing melanoma. Tumor-infiltrating lymphocytes (immune cells that penetrate the tumor) can destroy melanoma cells in a process called regression. Histologically, regression appears as areas where the tumor has been partially destroyed and replaced by inflammatory cells and scarring. The presence of regression in a melanoma specimen is actually a favorable prognostic sign, suggesting the patient's immune system is mounting an effective response against the cancer. This immune interaction is clinically important because it explains the rationale for immunotherapy treatments like checkpoint inhibitors, which enhance the immune system's ability to fight melanoma cells. If the patient's own immune system can control melanoma, the goal of therapy is to remove the brakes that the tumor uses to hide from immunity. Summary: Melanoma results from a combination of external factors (primarily UV exposure) and internal factors (genetic predisposition and immune status). The disease progresses through characteristic phases from superficial radial growth to deeper, more dangerous vertical growth. Understanding these principles of etiology and pathogenesis provides the foundation for understanding how melanoma is diagnosed, staged, and treated.